PROCEPT BioRobotics Corporation Revenue
PROCEPT BioRobotics Corporation (PRCT) reported Revenue of $94.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $94.50M, a 19.34% increase year-over-year.
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $83.13M, a 20.20% increase year-over-year.
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $76.38M, a 11.94% increase year-over-year.
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $83.33M, a 42.76% increase year-over-year.
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2025 was $308.05M, a 37.22% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2024 was $224.50M, a 64.84% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2023 was $136.19M, a 81.55% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation revenue from contract with customer, excluding assessed tax for fiscal 2022 was $75.01M, a 117.60% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $94.50M 10-Q · filed 2026-08-05 | $177.63M 10-Q · filed 2026-08-05 | $254.01M derived: sum of 3 quarters · filed 2026-08-05 | $337.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $83.13M 10-Q · filed 2026-04-30 | $159.51M derived: sum of 2 quarters · filed 2026-04-30 | $242.84M derived: sum of 3 quarters · filed 2026-04-30 | $322.02M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $76.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $159.71M derived: sum of 2 quarters · filed 2026-02-26 | $238.89M derived: sum of 3 quarters · filed 2026-08-05 | $308.05M 10-K · filed 2026-02-26 |
| 2025-09-30 | $83.33M 10-Q · filed 2025-11-05 | $162.51M derived: sum of 2 quarters · filed 2026-08-05 | $231.67M 10-Q · filed 2025-11-05 | $299.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $79.18M 10-Q · filed 2026-08-05 | $148.34M 10-Q · filed 2026-08-05 | $216.58M derived: sum of 3 quarters · filed 2026-08-05 | $274.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $69.16M 10-Q · filed 2026-04-30 | $137.40M derived: sum of 2 quarters · filed 2026-04-30 | $195.77M derived: sum of 3 quarters · filed 2026-04-30 | $249.12M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $68.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $126.61M derived: sum of 2 quarters · filed 2026-02-26 | $179.96M derived: sum of 3 quarters · filed 2026-02-26 | $224.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $58.37M 10-Q · filed 2025-11-05 | $111.72M derived: sum of 2 quarters · filed 2025-11-05 | $156.26M 10-Q · filed 2025-11-05 | $199.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $53.35M 10-Q · filed 2025-08-07 | $97.89M 10-Q · filed 2025-08-07 | $141.47M derived: sum of 3 quarters · filed 2026-02-26 | $176.57M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $44.54M 10-Q · filed 2025-05-02 | $88.12M derived: sum of 2 quarters · filed 2026-02-26 | $123.22M derived: sum of 3 quarters · filed 2026-02-26 | $156.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $43.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $78.68M derived: sum of 2 quarters · filed 2026-02-26 | $111.79M derived: sum of 3 quarters · filed 2026-02-26 | $136.19M 10-K · filed 2026-02-26 |
| 2023-09-30 | $35.10M 10-Q · filed 2024-10-28 | $68.21M derived: sum of 2 quarters · filed 2024-10-28 | $92.61M 10-Q · filed 2024-10-28 | $116.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $33.10M 10-Q · filed 2024-08-02 | $57.51M 10-Q · filed 2024-08-02 | $81.28M derived: sum of 3 quarters · filed 2025-02-27 | $101.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $24.40M 10-Q · filed 2024-05-02 | $48.18M derived: sum of 2 quarters · filed 2025-02-27 | $68.53M derived: sum of 3 quarters · filed 2025-02-27 | $85.22M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $23.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $44.13M derived: sum of 2 quarters · filed 2025-02-27 | $60.82M derived: sum of 3 quarters · filed 2025-02-27 | $75.01M 10-K · filed 2025-02-27 |
| 2022-09-30 | $20.35M 10-Q · filed 2023-11-02 | $37.04M derived: sum of 2 quarters · filed 2023-11-02 | $51.24M 10-Q · filed 2023-11-02 | $61.38M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $16.69M 10-Q · filed 2023-07-28 | $30.89M 10-Q · filed 2023-07-28 | $41.03M derived: sum of 3 quarters · filed 2024-02-28 | $49.69M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $14.20M 10-Q · filed 2023-05-04 | $24.34M derived: sum of 2 quarters · filed 2024-02-28 | $33.00M derived: sum of 3 quarters · filed 2024-02-28 | $41.48M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $10.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $18.81M derived: sum of 2 quarters · filed 2024-02-28 | $27.28M derived: sum of 3 quarters · filed 2024-02-28 | $34.47M 10-K · filed 2024-02-28 |
| 2021-09-30 | $8.67M 10-Q · filed 2022-11-04 | $17.14M derived: sum of 2 quarters · filed 2022-11-04 | $24.34M 10-Q · filed 2022-11-04 | $27.56M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $8.48M 10-Q · filed 2022-08-05 | $15.67M 10-Q · filed 2022-08-05 | $18.89M derived: sum of 3 quarters · filed 2022-08-05 | $21.00M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $7.19M 10-Q · filed 2022-05-06 | $10.41M derived: sum of 2 quarters · filed 2022-05-06 | $12.52M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $5.33M derived: sum of 2 quarters · filed 2022-03-22 | $7.72M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $2.11M 10-Q · filed 2021-11-05 | $4.50M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |